Accordingly, a G3BP antagonist downregulated RIG-I-stimulated G3BP1 methylation; hence, RIG-I and MAVS deficiency reduced osteogenic signals in VSMCs, attenuating arteriosclerosis (70). The gene discussed is G3BP1; the disease is arteriosclerosis disorder.